FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer By Ogkologos - January 22, 2026 489 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Sends Out Warning To Dollar Tree For Selling “Potentially Unsafe... November 20, 2019 Concurrent Intrathecal and Intravenous Nivolumab is Safe and Feasible with Preliminary... April 12, 2023 Life beyond cancer: Improving the long term side effects for children... September 22, 2022 FDA Approves Relugolix for Advanced Prostate Cancer January 7, 2021 Load more HOT NEWS FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for... How Cancer Survivorship Has Changed Over 25 Years: An Expert Perspective A Short-Course of Induction Chemotherapy Followed by Chemoradiotherapy Significantly Improves Survival... Forging Military Partnerships to Empower the Cancer Research Enterprise
